Citation

Boga SB, Deng Y, Zhu L, Nan Y, Cooper AB, Shipps GW, Doll R, Shih NY, Zhu H, Sun R, Wang T, Paliwal S, Tsui HC, Gao X, Yao X, Desai J, Wang J, Alhassan AB, Kelly J, Patel M, Muppalla K, Gudipati S, Zhang LK, Buevich A, Hesk D, Carr D, Dayananth P, Black S, Mei H, Cox K, Sherborne B, Hruza AW, Xiao L, Jin W, Long B, Liu G, Taylor SA, Kirschmeier P, Windsor WT, Bishop R, Samatar AA.: MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology. ACS Med Chem Lett, Volume 9 (7), 2018

Authors

Alhassan AB, Bishop R, Black S, Boga SB, Buevich A, Carr D, Cooper AB, Cox K, Dayananth P, Deng Y, Desai J, Doll R, Gao X, Gudipati S, Hesk D, Hruza AW, Jin W, Kelly J, Kirschmeier P, Liu G, Long B, Mei H, Muppalla K, Nan Y, Paliwal S, Patel M, Samatar AA., Sherborne B, Shih NY, Shipps GW, Sun R, Taylor SA, Tsui HC, Wang J, Wang T, Windsor WT, Xiao L, Yao X, Zhang LK, Zhu H, Zhu L

Journal

ACS Med Chem Lett

Year

2018

DOI

10.1021/acsmedchemlett.8b00220

PubMed

30034615

Machine-readable

REST APIRDF